share_log

Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets

Benzinga ·  Nov 7 10:02

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment